Celltech profits delay
Thursday 29 May 1997
However, Peter Fellner, chief executive, said the group's follow up treatment for the bowel condition, Crohn's disease, would replace at least a third of the value the company had lost after it was forced last week to abandon the sepsis drug, which was being developed in partnership with Bayer.
Dr Fellner said Bayer had returned the rights to the Crohn's disease drug and that Celltech had begun discussions with companies specialising in the gastrointestinal field.
He said that he expected to sign up a licencing partner on more favourable terms than with Bayer. "Septic shock was first, second and third on Bayer's list of priorities. Bayer had only agreed to develop the Crohn's drug on condition that the sepsis drug worked."
Dr Fellner said that pivotal trial data on the group's leukaemia drug being developed with American Home Products was expected this year.
The group said that the value would also come from other more early stage drugs including a new approach to the treatment of asthma. Dr Fellner said that the group had five or six years cash left at current burn rates. He added that the septic shock episode validated the group's strategy. "You can't run a pure biotech with low risk products and we do have high risk and innovative drugs. But we try to balance that with a low risk financial strategy, by having major partners who take on the costs of research."
Results for the six months to 31 March, announced yesterday, showed that the group had pounds 41m cash. Underlying losses rose from pounds 5m to pounds 5.9m after research costs climbed pounds 1.5m higher to pounds 10m.
The group's shares, which were over 600p before last week's announcement, firmed 4.5p to 338.5p.
- 1 Exclusive: Abusers using spyware apps to monitor partners reaches 'epidemic proportions'
- 2 Margaret Thatcher 'expressed fears of Asian rising' at Anglo-Irish summit in 1984
- 3 Top 10 travel destinations for 2015: From Haiti and Alaska to Namibia and Iceland
- 4 The 'Black Museum': After 150 years, public set to see exhibits from police’s grisly crime museum
- 5 The Unluckiest People of the Year 2014 (and one very unlucky giraffe)
Exclusive: Abusers using spyware apps to monitor partners reaches 'epidemic proportions'
Margaret Thatcher 'expressed fears of Asian rising' at Anglo-Irish summit in 1984
UK weather: Travel chaos continues as King's Cross train delays add to snow on roads
The 'Black Museum': After 150 years, public set to see exhibits from police’s grisly crime museum
The Unluckiest People of the Year 2014 (and one very unlucky giraffe)
British actor Idris Elba cannot star as James Bond because he is black, says shock jock Rush Limbaugh
Rozanne Duncan: Ukip expels councillor for 'jaw-dropping' comments made in BBC TV interview
Germany anti-Islam protests: 17,000 march on Dresden against 'Islamification of the West'
Ukip member gets into Christmas spirit with Union Flag plea to Santa 'for our country back'
BBC director Danny Cohen: Rising UK antisemitism makes me feel more uncomfortable than ever
Immigrants make UK racist, says Ukip councillor Trevor Shonk
iJobs Money & Business
Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...
Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...
Not specified: Selby Jennings: SVP Model Validation This top tiered investment...
Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...